TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cadrenal Therapeutics, Inc. ( (CVKD) ).
On November 18, 2025, Cadrenal Therapeutics, Inc. announced the filing of a prospectus supplement with the SEC for an ‘at the market offering’ program, allowing the sale of up to $3,438,062 of its common stock through H.C. Wainwright & Co., LLC. This move follows the company’s previous sale of $9,386,964 in shares under the same agreement. The offering is conducted under a registration statement effective since March 2024, and the agreement allows for flexible sales parameters. The company retains the right to suspend or terminate the agreement, and Wainwright will receive a 3% commission on sales.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Average Trading Volume: 25,017
Technical Sentiment Signal: Sell
Current Market Cap: $24.1M
See more insights into CVKD stock on TipRanks’ Stock Analysis page.